Redeye comments on Alzinova’s announcement of a new research collaboration with Amsterdam UMC aimed at developing a blood-based diagnostic test based on the company’s Aβ42CC technology. While this represents a somewhat unexpected commercial route, we view the initiative as strategically and scientifically well-motivated. If successful, the project could open an additional path to commercialization and strengthen the long-term value proposition of ALZ-101 through companion diagnostic opportunities.
LÄS MER
